...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
Reply New Message
Back To Forum List View
Icon president Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
4
BearDownAZ
Sep 04, 2018 08:52AM
Icon president Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
3
BearDownAZ
Sep 04, 2018 09:05AM

"Using CURATE.AI-suggested dosing of ZEN-3694 and enzalutamide, the patient achieved a durable response now ongoing for > 16 months."

Boo-yah! Take that mCRPC. I'm really excited to see a data update for the trial at the AGM/Corporate Update.

BDAZ

7 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply